MedPath

The effect of intravitreal injection of bevacizumab after vitrectomy for proliferative diabetic retinopathy

Not Applicable
Conditions
proliferative diabetic retinopathy
Registration Number
JPRN-UMIN000009801
Lead Sponsor
Tokyo medical university
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

It is IVB medication before an operation.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
(1) Primary endpoint Frequency of postoperative vitreous body re-bleeding (2) Secondary endpoint A. Evaluation of the activity of the new blood vessel by the anterior ocular segment photograph and a fundus-of-the-eye photograph B. Evaluation of the activity of the new blood vessel by fluorescence fundus-of-the-eye imaging C. The improvement factor of eyesight D. The improvement factor of the thickness of the retina by an optical interference fault meter E. The improvement factor of intraocular pressure
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath